VivoSeq
Infectious Disease

Bacterial Meningitis

9

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Bacterial Meningitis is an early-stage landscape with 9 programs across 2 companies. The most active players are GSK, Kenvue Brands. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

75/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 3K

Kenvue Brands

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Terminated1 · 20%
Unknown status1 · 20%

Clinical Trials

Trial Activity

Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis
Completed·KKamuzu University of Health Sciences·Phase 3·NCT00619203·466 enrolled
Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis
Completed·UUniversity of Helsinki·Phase 4·NCT01540838·375 enrolled
Daptomycin in Pediatric Patients With Bacterial Meningitis
Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 1·NCT01522105·1 enrolled
Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance
Unknown status·SShandong University·N/A·NCT04771884·300 enrolled
Infant Severe Sepsis and Bacterial Meningitis in Malawi
Completed·KKamuzu University of Health Sciences·Phase 4·NCT01247909·351 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)